From: Prospective changes in diastolic function in patients with rheumatoid arthritis
Univariable (n=158) | Multivariable (n=131) | |||||
---|---|---|---|---|---|---|
Demographics (baseline) | OR | 95% CI | p-value | OR | 95% CI | p-value |
Age, per year | 1.09 | 1.05–1.12 | <0.01 | 1.08 | 1.03–1.14 | 0.003 |
Male versus female | 1.36 | 0.58–3.21 | 0.48 | 0.45 | 0.12–1.70 | 0.24 |
Race/ethnicity | ||||||
White | REF | REF | ||||
Black | 0.59 | 0.23–1.51 | 0.27 | |||
Hispanic | 1 | 0.48–2.07 | 1.00 | ---- | ---- | ---- |
Other | 0.40 | 0.071–2.24 | 0.30 | |||
BMI, per kg/m2 | 1.03 | 0.98–1.08 | 0.26 | 0.96 | 0.89–1.04 | 0.36 |
RA characteristics (baseline) | ||||||
RA duration (square root), per year | 1.25 | 1.02–1.52 | 0.031 | 1.19 | 0.90–1.57 | 0.23 |
Joint deformities (square root) | 1.72 | 1.31–2.26 | <0.01 | ---- | ---- | ---- |
CDAI (square root), per unit | 1.24 | 1.01–1.53 | 0.037 | 1.39 | 1.02–1.90 | 0.034 |
DAS28CRP | 1.29 | 1.01–1.65 | 0.0041 | ---- | ---- | ---- |
RF (baseline) | ||||||
0: <15 (REF) | REF | REF | REF | REF | REF | |
1: 15–500 | 2.94 | 0.77–11.25 | 0.12 | 3.50 | 0.59–20.70 | 0.17 |
2: >500 | 4.44 | 0.94–21.00 | 0.060 | 4.44 | 0.58–33.88 | 0.15 |
CCP (baseline) | ||||||
0: <15.6 (REF) | REF | REF | REF | |||
1: 15.6–250 | 2.11 | 0.50–8.95 | 0.31 | ---- | ---- | ---- |
2: >250 | 2.1 | 0.50–8.73 | 0.31 | |||
Square root CRP, per mg/liter | 1.24 | 0.95–1.61 | 0.11 | ---- | ---- | ---- |
Log IL-6, per mg/liter | 1.19 | 0.90–1.58 | 0.21 | 0.88 | 0.58–1.33 | 0.54 |
Log BNP, per pg/mL | 1.54 | 0.77–3.08 | 0.22 | ---- | ---- | ---- |
Log troponin-I, per pg/mL | 1.84 | 1.32–2.56 | <0.01 | 1.097 | 0.66–1.81 | 0.72 |
Log galectin-3 ng/mL | 1.91 | 0.89–4.10 | 0.097 | ---- | ---- | ---- |
RA medication | ||||||
NSAIDs | 1.14 | 0.60–2.18 | 0.68 | ---- | ---- | ---- |
Prednisone | 1.08 | 0.54–2.14 | 0.83 | ---- | ---- | ---- |
Leflunomide | 4.48 | 1.18–16.98 | 0.027 | 7.18 | 1.19–43.4 | 0.032 |
Methotrexate | 1.07 | 0.55–2.07 | 0.84 | ---- | ---- | ---- |
TNF inhibitor | 0.94 | 0.47–1.89 | 0.86 | ---- | ---- | ---- |
Tocilizumab | 0.59 | 0.053–6.68 | 0.67 | ---- | ---- | ---- |
CV risk factors (baseline) | ||||||
Current smoker, yes versus no | 1.24 | 0.44–3.50 | 0.68 | ---- | ---- | ---- |
Ever smoker, yes versus no | 1.53 | 0.80–2.94 | 0.20 | 1.17 | 0.48–2.84 | 0.73 |
SBP (baseline), mm/Hg | 1.03 | 1.01–1.05 | 0.003 | 1.00 | 0.98–1.03 | 0.71 |
Statin use, yes versus no | 1.37 | 0.56–3.32 | 0.49 | ---- | ---- | ---- |
Total cholesterol, per mg/dL | 1.00 | 0.99–1.01 | 0.62 | ---- | ---- | ---- |
LDL, per mg/dL | 1.00 | 0.99–1.01 | 0.88 | ---- | ---- | ---- |
Square root HDL, per mg/dL | 1.08 | 0.82–1.43 | 0.57 | ---- | ---- | ---- |
PET/CT cardiac measures (baseline) | ||||||
CAC score>100 | 4.42 | 1.75–11.22 | 0.002 | ---- | ---- | ---- |
CAC score>300 | 5.63 | 1.52–20.8 | 0.010 | 6.76 | 0.73–62.23 | 0.091 |
Log mean myocardial SUV, per unit | 1.52 | 0.83–2.77 | 0.17 | ---- | ---- | ---- |
Log max myocardial SUV, per unit | 1.64 | 0.97–2.71 | 0.066 | 1.37 | 0.72–2.60 | 0.34 |
Myocardial flow reserve (MFR) | 0.75 | 0.43–1.30 | 0.31 | ---- | ---- | ---- |
Prob>F | <0.001 | |||||
Pseudo R-Squared | 0.26 |